CD20‐depleting therapy in autoimmune diseases: from basic research to the clinic
- 1 February 2010
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 267 (3) , 260-277
Abstract
Abstract. Perosa F, Prete M, Racanelli V, Dammacco F (University of Bari Medical School, Bari, Italy). CD20‐depleting therapy in autoimmune diseases: from basic research to the clinic (Review). J Intern Med 2010; 267: 260–277.The B lymphocyte‐associated antigen CD20 is becoming an important immunotherapy target for autoimmune diseases, although its biological function has not been defined. Besides rheumatoid arthritis, growing experience with B cell‐depleting therapy indicates that it may be effective in Sjögren’s syndrome, dermatomyositis–polymyositis, systemic lupus erythematosus and some types of vasculitides. However, controlled clinical trials are still lacking for some of these indications. Infection has not been seen as a major limitation to this therapy, but reports of progressive multifocal leukoencephalopathy in an extremely small number of patients are of concern. Here, we review the therapeutic actions of anti‐CD20 antibodies, and the recent and ongoing clinical trials with CD20‐depleting therapy in autoimmune diseases.Keywords
This publication has 145 references indexed in Scilit:
- A retrospective seven‐year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patientsArthritis Care & Research, 2009
- Idiotype vaccination for lymphoma: moving towards optimisationLeukemia & Lymphoma, 2009
- Rituximab in refractory pemphigus vulgarisDermatologic Therapy, 2008
- Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysisAnnals of Hematology, 2007
- A Single Cycle of Rituximab for the Treatment of Severe PemphigusNew England Journal of Medicine, 2007
- Rituximab for treatment-resistant extensive Wegener`s granulomatosis—additive effects of a maintenance treatment with leflunomideClinical Rheumatology, 2007
- Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesisNature Clinical Practice Rheumatology, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Rituximab therapy for childhood-onset systemic lupus erythematosusThe Journal of Pediatrics, 2006
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004